PRISM Mid-Day Movers: Pharmaceuticals and Global Health are Today’s Leaders.
Shares of Biodexa Pharmaceuticals plc (Nasdaq: BDRX) are rallying, recently trading around $1.05, up roughly 70% on the day as heavy volume floods into this beaten‑down micro‑cap oncology name. Even after today’s spike, the stock is still down more than 90% over the past year and carries a sub‑$1 million market cap ahead of a planned 1‑for‑5 ADR reverse split on April 6, 2026, leaving BDRX a highly speculative, catalyst‑driven biotech focused on late‑stage programs in familial adenomatous polyposis and other difficult‑to‑treat cancers where any clinical or partnering update can trigger outsized price swings.
Shares of Lexaria Bioscience Corp. (Nasdaq: LEXX) are back in focus as the micro‑cap hovers just under the $1.00 level, up about 17% while lining up its next wave of GLP‑1 data catalysts. The company recently reported positive final results from Human Pilot Study #5 showing its oral DehydraTECH‑liraglutide performed comparably to injected Saxenda and has now launched a 2026 R&D program built around one new human GLP‑1 study and two large multi‑arm animal studies using semaglutide, retatrutide, amycretin and cannabidiol, all aimed at strengthening its IP and securing pharma partnerships.
Other Notable Movers:
BioStem Technologies (BSEM) up 16%
Korro Bio (KRRO) up 10%
Lipocine Inc (LPCN) down -78%
